BS PHARM KOREA Expands INHILO+ Through Dongkook Partnership

BS PHARM KOREA has moved to solidify INHILO+ market position through a domestic distribution partnership with Dongkook Pharmaceutical and concurrent clinical evaluation in South Korea. The dual-molecular hyaluronic acid skin booster is advancing its market development through both commercial channels and scientific validation.

The partnership with Dongkook Pharmaceutical represents a strategic shift toward establishing deeper market penetration within South Korea. Dongkook Pharmaceutical will handle distribution of the product domestically, positioning INHILO+ within the company's existing retail and clinical networks. This arrangement allows BS PHARM KOREA to leverage established infrastructure while maintaining focus on product development and clinical evidence generation.

Simultaneously, an ongoing clinical evaluation program is underway to support INHILO+ efficacy claims in the South Korean market. Clinical data generation serves dual purposes: it strengthens regulatory positioning and provides the marketing support necessary for premium positioning in the competitive skin booster category. The timing aligns with heightened consumer interest in injectable and topical hyaluronic acid products across Asia-Pacific markets.

The dual-molecular formulation of INHILO+ differentiates it from single-chain hyaluronic acid competitors by combining high and low molecular weight variants. This molecular strategy targets both superficial hydration and deeper dermal penetration, potentially broadening its appeal across different skin concerns and consumer demographics.

For BS PHARM KOREA, the Dongkook arrangement reduces direct distribution costs while accelerating market access. For Dongkook, INHILO+ fills a gap in its aesthetic dermatology portfolio. The clinical program generates the third-party validation increasingly demanded by Korean consumers and healthcare providers evaluating skin health products.

This development signals BS PHARM KOREA's confidence in INHILO+ commercial viability and suggests potential for similar distribution partnerships in other Asia-Pacific territories where hyaluronic acid boosters face rising competition.